by The global radioembolization therapy market is experiencing steady expansion, driven by the increasing burden of liver cancer and the growing demand for minimally invasive oncology treatments. According to recent market estimates, the industry is projected to grow significantly over the next decade, supported by technological innovation and rising healthcare investments worldwide.
Read Also: Low Glycemic Index Rice Market
Radioembolization Therapy Market Size in 2026
The global radioembolization therapy market size was valued at USD 1.19 billion in 2025 and is expected to increase from USD 1.26 billion in 2026 to approximately USD 2.15 billion by 2035, expanding at a CAGR of 7.64% from 2026 to 2035.
This growth is primarily fueled by the increasing prevalence of liver cancer, rising adoption of targeted therapies, and advancements in interventional oncology technologies.
Market Overview
Radioembolization therapy is an advanced, minimally invasive treatment used mainly for liver cancers. It involves delivering radioactive microspheres—most commonly Yttrium-90—directly into tumors via the hepatic artery. This targeted approach enables high-dose radiation delivery while minimizing damage to surrounding healthy tissues.
The therapy is widely used in treating:
- Primary liver cancer (hepatocellular carcinoma)
- Metastatic liver cancer
- Unresectable tumors
Its dual mechanism—combining embolization and radiation—makes it a powerful alternative to traditional chemotherapy and surgery.
Key Market Highlights
- North America dominated the market in 2025 due to advanced healthcare infrastructure
- Asia Pacific is the fastest-growing region driven by rising liver cancer cases
- Yttrium-90 microspheres held the largest market share by product type
- Selective Internal Radiation Therapy (SIRT) led by procedure type
- Primary liver cancer remained the leading application segment
Growth Drivers of the Market
Rising Incidence of Liver Cancer
The increasing global prevalence of liver cancer is a major growth driver. Factors such as hepatitis infections, alcohol consumption, and lifestyle-related diseases contribute significantly to rising cases.
Demand for Minimally Invasive Treatments
Patients and healthcare providers increasingly prefer minimally invasive procedures due to:
- Reduced hospital stays
- Faster recovery time
- Lower complication risks
Advancements in Medical Technology
Technological innovations in imaging (MRI, PET, SPECT) and catheter-based delivery systems have significantly improved precision and outcomes in radioembolization therapy.
Role of Advanced Technologies in Market Expansion
Technological integration is transforming the radioembolization therapy landscape:
- AI-powered treatment planning improves dose accuracy
- 3D imaging and voxel-based dosimetry enhance tumor targeting
- SPECT and PET imaging enable better treatment verification
- Machine learning algorithms assist in predicting patient outcomes
These advancements are helping clinicians deliver safer, more personalized treatments.
Market Trends
Increasing Adoption of SIRT
Selective Internal Radiation Therapy (SIRT) is becoming the standard for treating unresectable liver tumors due to its effectiveness and targeted approach.
Personalized Oncology Treatments
Customized dosimetry and patient-specific treatment planning are gaining traction, improving therapeutic outcomes.
Shift Toward Curative-Intent Procedures
There is a growing trend toward segmental radioembolization, which focuses on delivering high radiation doses to specific tumor regions, aiming for curative results rather than palliative care.
Segmental Analysis
By Product Type
Yttrium-90 Microspheres (Dominant Segment)
- Widely used and clinically validated
- Strong global adoption and physician familiarity
- High effectiveness in tumor control
Holmium-166 Microspheres (Fastest Growing)
- Offers theranostic capabilities
- Enables both imaging and treatment
- Supports personalized dosimetry
By Procedure Type
Selective Internal Radiation Therapy (SIRT)
- Leading procedure in 2025
- Standard treatment for unresectable liver cancer
- Increasing integration with immunotherapy
Segmental Radioembolization
- Fastest-growing segment
- Enables high-dose targeted treatment
- Reduces radiation exposure to healthy tissues
By Technology
Trans-Arterial Radioembolization (TARE) dominated the market due to:
- High precision
- Fewer side effects
- Effectiveness in advanced-stage cancer
By Application
Primary Liver Cancer
- Largest market share in 2025
- Driven by increasing hepatocellular carcinoma cases
Metastatic Liver Cancer
- Fastest-growing segment
- Rising colorectal cancer cases fueling demand
Regional Insights
North America
North America led the global market due to:
- Advanced healthcare infrastructure
- High adoption of innovative technologies
- Strong presence of key industry players
- Favorable reimbursement policies
The United States remains the largest contributor, with widespread use of minimally invasive oncology treatments.
Asia Pacific
Asia Pacific is expected to witness the fastest growth due to:
- Increasing liver cancer prevalence
- Expanding healthcare infrastructure
- Government investments in nuclear medicine
- Rising awareness of advanced therapies
Countries like China and India are emerging as key growth markets.
Europe
Europe is also showing steady growth, supported by:
- Increasing cancer burden
- Adoption of advanced radiotherapy techniques
- Strong regulatory and healthcare frameworks
Competitive Landscape
The radioembolization therapy market is highly competitive, with key players focusing on innovation, partnerships, and product approvals.
Major Companies Include:
- Sirtex Medical
- Boston Scientific Corporation
- Terumo Corporation
- Merit Medical Systems, Inc.
- Varian Medical Systems
- Guerbet
- TriSalus Life Sciences
Recent Developments
- July 2025: FDA approved SIR-Spheres Y-90 resin microspheres for treating unresectable hepatocellular carcinoma
- April 2025: China introduced export regulations affecting rare earth elements used in medical imaging
These developments highlight ongoing innovation and regulatory shifts shaping the industry.
Future Outlook
The radioembolization therapy market is expected to witness robust growth over the next decade, driven by:
- Rising demand for targeted cancer therapies
- Integration of AI and precision medicine
- Expansion of healthcare infrastructure in emerging economies
- Increasing adoption of minimally invasive procedures
As technology continues to evolve, radioembolization therapy is likely to become a cornerstone in liver cancer treatment, offering improved survival rates and better quality of life for patients.
Conclusion
The global radioembolization therapy market is on a strong growth trajectory, with its size expected to reach USD 2.15 billion by 2035. The combination of rising cancer prevalence, technological advancements, and increasing preference for minimally invasive treatments is driving the market forward.
With continuous innovation and expanding global access, radioembolization therapy is set to play a crucial role in the future of oncology care.
Get Sample Copy: https://www.precedenceresearch.com/sample/7897
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
- Single Loop Controller Market Size to Hit USD 6.85 Billion by 2035 - March 31, 2026
- Surface Roughness Measurement Market Size to Hit USD 2.27 Billion by 2035 - March 31, 2026
- 8k Technology Market Size to Hit USD 657.82 Billion by 2035 - March 31, 2026
